About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT02329184

Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461

The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a sequential group, single ascending (oral) dose stu...

Lead sponsor: MyoKardia, Inc.•7 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

MyoKardia, Inc.

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Diagnosed with HCM
•Normal left ventricular ejection fraction (LVEF)
•NYHA class I, II or III

Exclusion Criteria

•Inherited metabolic disorders, myocardial infiltration or cardiofaciocutaneous syndrome (e.g., Noonan's, Fabry's).
•History of clinically important atrial or ventricular arrhythmias
•History of positive human immunodeficiency virus (HIV) test and/or seropositive for hepatitis C virus (HCV) or hepatitis B virus (HBV)..

Related studies

RECRUITINGPhase 1/2

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCT05836259 · Hypertrophic Cardiomyopathy

HCMR Re-Imaging Study

NCT07054073 · Hypertrophic Cardiomyopathy (HCM)

Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)

NCT07344480 · Hypertrophic Cardiomyopathy (HCM), Heart Failure, and more

RECRUITINGEARLY Phase 1

Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy

NCT06433050 · Hypertrophic Cardiomyopathy Without Obstruction

Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes

NCT07382128 · HCM - Hypertrophic Cardiomyopathy, Anderson Fabry Disease, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 14, 2016Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment15

Start dateDec 2014

Last updatedSep 14, 2016

Condition

Hypertrophic Cardiomyopathy

Locations shown

Scottsdale, Arizona

Cypress, California

Stanford, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 14, 2016Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions